PNEUMOVAX 23 ( VACUNA ANTINEUMOCOCCICA POLIVALENTE) solución inyectable Uruguay - español - Ministerio de Salud (Dirección Oficina Central)

pneumovax 23 ( vacuna antineumococcica polivalente) solución inyectable

cibeles - solución inyectable - vacuna neumococo 23 serotipos (polisacáridos capsulares) 0,5 ml inyectable

Mhyosphere PCV ID Unión Europea - español - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

METPURE XL-23.75 23.75mg TABLETA DE LIBERACION PROLONGADA Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

metpure xl-23.75 23.75mg tableta de liberacion prolongada

emcure pharma peru sociedad anonima cerrada - droguerÍa - tableta de liberacion prolongada - por mililitro - - metoprolol

CircoMax Myco Unión Europea - español - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - inmunológicos para suidos - los cerdos (de engorde) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

CHUSPISOL 10 WG GRÁNULOS DISPERSABLES 10% Chile - español - ISPC (Instituto de Salud Pública de Chile)

chuspisol 10 wg gránulos dispersables 10%

comercializadora crandon chile ltda. - tiametoxam 100% n°cas:153719-23-4 - tiametoxam 100% n°cas:153719-23-4 10,000 g - insecticidas para el control de moscas.

RIXATHON Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

rixathon

sandoz gmbh austria - rituximab ¹ 10 mg/ml ¹ rituximab se suministra como solución a granel gp2013 que contiene 23.0 -37.0 mg/ml de rituximab. está formulado a ph 6.5 con tampón citrato 2.5 mn - concentrado para solucion para infusion - cada vial contiene: rituximab¹ 10 mg/ml ¹ rituximab se suministra como solución a granel gp2013 que contiene 23.0 -37.0 mg/ml de rituximab. está formulado a ph 6.5 con tampón citrato 2.5 mn

BEROCCA PERFORMANCE COMPRIMIDOS EFERVESCENTES Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

berocca performance comprimidos efervescentes

bayer consumer care a.g. [ch] switzerland - tiamina 15.0 mg riboflavina 15.0 mg piridoxina clorhidrato 10.0 mg cianocobalamina 0,01 mg nicotinamida 50 mg Ácido pantoténico 23.0 mg biotina 0.15mg Ácido ascórbico 500 mg Ácido fólico 0.4 mg calcio 100.00 mg magnesio 100.00 mg zinc 10.0 mg - comprimidos efervescentes - cada comprimido efervescente contiene: cloruro de ester monofosfórico de tiamina 2h2o 19.467 mg (incluye 5% exceso) (equivale a 15.0 mg de vitamina b1 (tiamina)) fosfato sódico de riboflavina 2h2o 21.530 mg (incluye 5% exceso) (equivale a 15.0 mg de vitamina b2 (riboflavina)) clorhidrato de piridoxina 11.00 mg (incluye 10% exceso) (equivale a 10.0 mg de vitamina b6 (piridoxina clorhidrato)) cianocobalamina 0.1% 11.00 mg (incluye 10% exceso) nicotinamida (niacinamida) 52.500 mg (incluye 5% exceso) pantotenato de calcio 27.500 mg (incluye 10% exceso) (equivale a 23.0 mg de Ácido pantoténico) biotina 0.165 mg (incluye 10% exceso) Ácido ascórbico 525.000 mg (incluye 5% exceso) (equivale a 500 mg de vitamina c (Ácido ascórbico) Ácido fólico 0.440 mg (incluye 10% exceso) carbonato de calcio ?????????????? 243.974 mg + pantotenato de calcio equivalente a 100.0 mg de calcio ver pantotenato de calcio carbonato de magnesio pesado 194.822 mg + sulfato de magnesio dihidratado 328.200 mg (equivalen a 100.00 mg de magnesio) citrato de zinc trihidratado 32.0513 mg (equivale a 10.0 mg de zinc)

CLAVOXINE FORTE POLVO PARA SUSPENSION ORAL Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

clavoxine forte polvo para suspension oral

julpharma group s.a. [uy] uruguay - amoxicilina trihidrato 23.04 g clavulanato de potasio 6.00 g - polvo para reconstituir suspension oral - cada 100 g de polvo contiene: amoxicilina trihidrato 23.04 g clavulanato de potasio 6.00 g